# EDGAR Filing Document

**Accession Number:** 0001340243
**File Stem:** 0001628280-23-007423
**Filing Date:** 2023-3
**Character Count:** 7300
**Document Hash:** 56ec342c3efe2b25bcc1e8a79a668813
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-007423.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001628280-23-007423

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20230310

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MorphoSys AG
- **CENTRAL INDEX KEY:** 0001340243
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** 2M
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38455
- **FILM NUMBER:** 23721553

**BUSINESS ADDRESS:**
- **STREET 1:** SEMMELWEISSTR. 7
- **CITY:** PLANEGG
- **STATE:** 2M
- **ZIP:** 82152
- **BUSINESS PHONE:** 49 89 89927-0

**MAIL ADDRESS:**
- **STREET 1:** SEMMELWEISSTR. 7
- **CITY:** PLANEGG
- **STATE:** 2M
- **ZIP:** 82152

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MORPHOSYS AG
- **DATE OF NAME CHANGE:** 20050929

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2023**

**COMMISSION FILE NUMBER 001-38455**

**MorphoSys AG**

**Semmelweisstrasse 7**

**82152 Planegg**

**Germany**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

------

On March 9, 2023, MorphoSys AG (the "Company") published the press release "Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023. "

**<u>Exhibits</u>**

99.1&nbsp;&nbsp;&nbsp;&nbsp;<u>[Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023](a230310_exhibit991.htm)</u>

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**&nbsp;&nbsp;&nbsp;&nbsp;**MORPHOSYS AG (Registrant)

Date: March 10, 2023&nbsp;&nbsp;&nbsp;&nbsp;By:&nbsp;&nbsp;&nbsp;&nbsp;<u>/s/ i.A. Kristina Grötsch</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Kristina Grötsch

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:&nbsp;&nbsp;&nbsp;&nbsp;Senior Specialist Investor Relations

&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;By: <u>/s/ i.A. Isabelle Degbegni&nbsp;&nbsp;&nbsp;&nbsp;</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Isabelle Degbegni

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:&nbsp;&nbsp;&nbsp;&nbsp; Director Investor Relations

## Exhibit 99.1

![](a230310_exhibit991001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Page 1 Conference Call Alert Planegg/Munich, Germany, March 9, 2023 Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023 MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on March 16, 2023 at 01:00 pm CET (12:00 pm GMT; 8:00 am EDT) to present the results for the financial year 2022 and provide an outlook for 2023. The conference call will start with a presentation by the Management team followed by a Q&A session. A live webcast and slides will be made available at the Investors section on MorphoSys' website, www.morphosys.com. To join the conference call via phone, participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call via the following website: https://services.choruscall.it/DiamondPassRegistration/register?confirmationNumber=347823 8&linkSecurityString=469447192 Please dial in 10 minutes before the beginning of the conference. A replay of the conference will also be available at the corporate website following the live event. About MorphoSys At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter and LinkedIn. Forward Looking Statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward- looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these

------

![](a230310_exhibit991002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Page 2 uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward- looking statements, unless specifically required by law or regulation. For more information, please contact: Media Contacts: Thomas Biegi Vice President Tel.: +49 (0)89 / 89927 26079 thomas.biegi@morphosys.com Investor Contacts: Dr. Julia Neugebauer Head of Investor Relations Tel: +49 (0)89 / 899 27 179 julia.neugebauer@morphosys.com Eamonn Nolan Director Tel: +1 617-548-9271 eamonn.nolan@morphosys.com

------